Catheter ablation (CA) is an established therapeutic option for patients with symptomatic
atrial fibrillation (AF). During the procedure, patients are usually sedated and analgesized,
most commonly by administration of Propofol combined with opioids under the supervision of
the electrophysiologist. However, due to the depressive effect of Propofol on the respiratory
system, this regimen is not without risk. Dexmedetomidine is a highly selective alpha 2
agonist that demonstrates both analgesic and hypnotic properties with only weak effect on the
respiratory system. The pharmacological profile of Dexmedetomidine may be advantageous for
sedation during CA of AF. The aim of this randomized trial is to test this hypothesis and
explore the safety and efficacy of Dexmedetomidine during CA of AF.